Edgewise Therapeutics reported net income of -$57.58M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 49.30M | 37.53M | 49.56M | 49.78M | 51.84M | 63.26M | 63.27M | 63.46M | 63.46M | 70.45M | 93.28M | 93.64M | 94.41M | 94.84M | 95.21M | 105.34M | 105.76M | 106.25M | 107.48M | 107.78M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.88M | 9.09M | 11.12M | 12.40M | 13.89M | 16.61M | 19.88M | 19.56M | 23.79M | 27.68M | 27.69M | 30.68M | 32.22M | 36.37M | 36.76M | 33.56M | 37.48M | 43.59M | 42.65M | 47.55M | ||||||
| Selling, General & AdministrativeSG&A | 3.20M | 3.73M | 3.70M | 4.09M | 4.37M | 5.47M | 5.83M | 5.78M | 5.67M | 6.18M | 7.06M | 7.43M | 8.21M | 9.17M | 9.20M | 9.05M | 9.38M | 12.38M | 11.46M | 14.39M | ||||||
| Operating ExpensesOpex | 13.08M | 12.82M | 14.83M | 16.49M | 18.26M | 22.08M | 25.70M | 25.34M | 29.45M | 33.86M | 34.75M | 38.11M | 40.43M | 45.54M | 45.96M | 42.61M | 46.86M | 55.98M | 54.12M | 61.94M | ||||||
| Operating IncomeOp. Inc | -13.08M | -12.82M | -14.83M | -16.49M | -18.26M | -22.08M | -25.70M | -25.34M | -29.45M | -33.86M | -34.75M | -38.11M | -40.43M | -45.54M | -45.96M | -42.61M | -46.86M | -55.98M | -54.12M | -61.94M | ||||||
| EBIT | -13.08M | -12.82M | -14.83M | -16.49M | -18.26M | -22.08M | -25.70M | -25.34M | -29.45M | -33.86M | -34.75M | -38.11M | -40.43M | -45.54M | -45.96M | -42.61M | -46.86M | -55.98M | -54.12M | -61.94M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.13M | 0.13M | 0.17M | 0.42M | 0.76M | 2.66M | 2.87M | 3.87M | 3.74M | 3.72M | 6.23M | 6.61M | 6.30M | 5.88M | 5.16M | 6.50M | 6.19M | 5.76M | 5.10M | 4.62M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.13M | 0.13M | 0.17M | 0.42M | 0.76M | 2.66M | 2.87M | 3.87M | 3.74M | 3.72M | 6.23M | 6.61M | 6.30M | 5.88M | 5.16M | 6.50M | 6.19M | 5.76M | 5.10M | 4.62M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -12.95M | -12.70M | -14.66M | -16.07M | -17.50M | -19.41M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M | ||||||
| Profit After TaxPAT | -12.95M | -13.19M | -14.66M | -16.07M | -17.50M | -18.59M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.31M | -40.67M | -50.22M | -49.01M | -57.58M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -12.95M | -12.70M | -14.66M | -16.07M | -17.50M | -19.41M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -12.95M | -12.70M | -14.66M | -16.07M | -17.50M | -19.41M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M | ||||||
| Income towards Parent CompanyParent Net Inc | -12.95M | -12.70M | -14.66M | -16.07M | -17.50M | -19.41M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M | ||||||
| Net Income towards Common StockholdersNet Income | -12.95M | -12.70M | -14.66M | -16.07M | -17.50M | -19.41M | -22.84M | -21.47M | -25.71M | -30.14M | -28.52M | -31.50M | -34.13M | -39.66M | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.26 | -0.34 | -0.30 | -0.32 | -0.34 | -0.36 | -0.36 | -0.34 | -0.41 | -0.47 | -0.33 | -0.34 | -0.36 | -0.43 | -0.43 | -0.34 | -0.39 | -0.49 | -0.46 | -0.53 | ||||||
| EPS (Diluted) | -0.26 | -0.34 | -0.30 | -0.32 | -0.34 | -0.36 | -0.36 | -0.34 | -0.41 | -0.47 | -0.33 | -0.34 | -0.36 | -0.43 | -0.43 | -0.34 | -0.39 | -0.49 | -0.46 | -0.53 | ||||||
| Shares Outstanding | 49.26M | 37.53M | 49.54M | 49.62M | 51.84M | 53.59M | 63.27M | 63.38M | 63.46M | 63.72M | 87.57M | 93.52M | 93.81M | 92.41M | 95.13M | 104.94M | 105.49M | 102.93M | 107.12M | 107.67M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 49.26M | 37.53M | 49.54M | 49.62M | 51.84M | 53.59M | 63.27M | 63.38M | 63.46M | 63.72M | 87.57M | 93.52M | 93.81M | 92.41M | 95.13M | 104.94M | 105.49M | 102.93M | 107.12M | 107.67M | ||||||
| EBITDA | -13.08M | -12.82M | -14.83M | -16.49M | -18.26M | -22.08M | -25.70M | -25.34M | -29.45M | -33.86M | -34.75M | -38.11M | -40.43M | -45.54M | -45.96M | -42.61M | -46.86M | -55.98M | -54.12M | -61.94M |